Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate.

@article{Stock2012EfficacyAS,
  title={Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate.},
  author={Thomas C. Stock and Bradley J. Bloom and Nathan Wei and Saliha Ishaq and Won Yeul Park and Xin Wang and Pankaj Gupta and Charles A. Mebus},
  journal={The Journal of rheumatology},
  year={2012},
  volume={39 4},
  pages={720-7}
}
OBJECTIVE To evaluate efficacy and safety of CE-224,535, a selective P2X(7) receptor antagonist, versus placebo, in patients with active rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX). METHODS In our phase IIA study (ClinicalTrials.gov no. NCT00628095; A6341009), patients aged ≥ 18 years with active RA were randomized to receive… CONTINUE READING